Successful CD34+ cell mobilisation is predictive of a survival advantage to patients with myeloma undergoing peripheral blood stem cell transplantation.

被引：0
|
作者：
Williams, CD [1 ]
Watts, MJ [1 ]
Sullivan, AM [1 ]
Leverett, D [1 ]
Linch, DC [1 ]
Goldstone, AH [1 ]
机构：
[1] UCL HOSP, LONDON, ENGLAND
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1996年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：302 / 302
页数：1
相关论文
共 50 条
  • [1] Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell (PBSC) transplantation.
    Klaus, J.
    [J]. CYTOTHERAPY, 2006, 8
  • [2] Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation
    Klaus, Jens
    Herrmann, Doris
    Breitkreutz, Iris
    Hegenbart, Ute
    Mazitschek, Uta
    Egerer, Gerlinde
    Cremer, Friedrich W.
    Lowenthal, Ray M.
    Huesing, Johannes
    Fruehauf, Stefan
    Moehler, Thomas
    ho, Antny D. Ho
    Goldschmidt, Hartmut
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 78 (01) : 21 - 28
  • [3] High CD34+ cell dose is a significant factor for hematologic reconstitution of patients with multiple myeloma (MM) or AL-amyloidosis undergoing autologous peripheral blood stem cell transplantation.
    Klaus, J
    Herrmann, D
    Hegenbart, U
    Egerer, G
    Cremer, FW
    Breitkreutz, I
    Benner, A
    Fruehauf, S
    Moehler, T
    Ho, AD
    Goldschmidt, H
    [J]. BLOOD, 2004, 104 (11) : 328A - 328A
  • [4] Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation
    C. Hicks
    R. Wong
    A. Manoharan
    Y. L. Kwan
    [J]. Annals of Hematology, 2007, 86 : 591 - 598
  • [5] Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation
    Hicks, C.
    Wong, R.
    Manoharan, A.
    Kwan, Y. L.
    [J]. ANNALS OF HEMATOLOGY, 2007, 86 (08) : 591 - 598
  • [6] Endogenous production of cytokines in autologous and allogeneic CD34+ selected peripheral blood stem cell transplantation.
    Vizcarra, E
    Solano, C
    Marugan, I
    Benet, I
    Arbona, C
    Gutiérrez, A
    García-Conde, J
    [J]. BONE MARROW TRANSPLANTATION, 1999, 23 : S82 - S82
  • [7] Peripheral blood stem cell mobilisation in lymphoma patients candidates to autologous transplantation. Development of a predictive score
    Rossi, G.
    Skert, C.
    Morello, E.
    Almici, C.
    Arcaini, L.
    Basilico, C.
    Botto, B.
    Castelli, A.
    Pica, G.
    Ripamonti, F.
    Salvi, F.
    Carella, A. M.
    Gaidano, G.
    Levis, A.
    Nosari, A.
    Russo, D.
    Vitolo, U.
    [J]. BONE MARROW TRANSPLANTATION, 2012, 47 : S22 - S22
  • [8] Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation
    Singh, Anurag K.
    Savani, Bipin N.
    Albert, Paul S.
    Barrett, A. John
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (03) : 339 - 344
  • [9] Analysis of viable CD133+/CD34+AND CD34+stem cell subsets in prediction of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks, C.
    [J]. CYTOTHERAPY, 2006, 8
  • [10] Circulating CD34+ cell counts are predictive of CD34+ peripheral blood progenitor cell yields
    Bandarenko, N
    Sims, LC
    Brecher, ME
    [J]. TRANSFUSION, 1997, 37 (11-12) : 1218 - 1218
12345